Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tuberculosis therapy: past, present and future.

M D Iseman1

  • 1Dept of Medicine, National Jewish Medical and Resource Centre, Denver, CO 80206-9982, USA. isemanm@njc.org

The European Respiratory Journal. Supplement
|August 10, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A new approach to treating patients with MDR-TB?

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2003
Same author

Vulnerability to tuberculosis and William Stead, a tireless scholar.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2001
Same author

Some healthy skepticism about inhaled therapy for tuberculosis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001
Same author

Vertebral osteomyelitis due to infection with nontuberculous Mycobacterium species after blunt trauma to the back: 3 examples of the principle of locus minoris resistentiae.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001
Same author

Tuberculosis-still the #1 killer in infectious diseases.

International journal of clinical practice. Supplement·2001
Same author

Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001
Same journal

Current status of lung transplantation.

The European respiratory journal. Supplement·2003
Same journal

Treatment of chronic respiratory failure: lung volume reduction surgery versus rehabilitation.

The European respiratory journal. Supplement·2003
Same journal

Home ventilation.

The European respiratory journal. Supplement·2003
Same journal

Mechanical ventilation: invasive versus noninvasive.

The European respiratory journal. Supplement·2003
Same journal

Respiratory failure in chronic obstructive pulmonary disease.

The European respiratory journal. Supplement·2003
Same journal

Physical and biological triggers of ventilator-induced lung injury and its prevention.

The European respiratory journal. Supplement·2003
See all related articles

Tuberculosis (TB) treatment has evolved significantly with new drugs and shorter regimens. However, drug resistance necessitates developing novel therapies to combat TB effectively, especially in resource-poor settings.

Area of Science:

  • Medical Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Tuberculosis (TB) treatment has progressed through several key milestones since the 1940s.
  • Effective multi-drug regimens have been developed, shortening treatment durations significantly.
  • The emergence of drug-resistant TB strains poses a major global health threat.

Purpose of the Study:

  • To review the historical advancements in tuberculosis therapy.
  • To highlight the challenges posed by drug resistance and treatment noncompliance.
  • To emphasize the need for new anti-TB medications and treatment strategies.

Main Methods:

  • Historical review of tuberculosis treatment regimens.
  • Analysis of the impact of drug discovery on TB cure rates.

Related Experiment Videos

  • Examination of challenges in TB control, including drug resistance and co-infection with HIV.

    • Main Results:

    • Discovery of streptomycin and PAS in 1944.
    • Development of triple therapy (streptomycin, PAS, isoniazid) in 1952.
    • Shortened treatment durations to 9 months (isoniazid, rifampin) in the 1970s and 6 months (adding pyrazinamide) in the 1980s.
    • Intermittent regimens show promise but face challenges in resource-poor settings.
    • Drug-resistant TB strains are a growing concern globally.

    Conclusions:

    • New anti-TB drugs are crucial to shorten therapy, extend dosing intervals, and overcome resistance.
    • Optimal treatment strategies for patients with HIV and TB are needed, considering drug interactions.
    • Further research into immune modulation could offer novel approaches to TB treatment.